• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1280275 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type" D6 O' l" h, U6 I% l) Q3 v/ N9 H
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
2 _3 @3 Q  d2 Y6 `. p7 @6 @+ Author Affiliations) k# z2 x8 s7 x

6 L* M4 D  e  a* q1 M3 b6 t, `1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
! S1 \4 ^% Y$ W1 ~' q9 Y  ?2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 9 E% D* {6 C  A! y+ T# P* z( X
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
" S: t4 Z. ]7 O1 ?1 N% s' U9 T1 d0 z4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan " |% D. G$ a( i$ L& P5 ]' |
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
% k! ?6 N0 e: i( y. G6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
) v! A$ i. K0 t7Kinki University School of Medicine, Osaka 589-8511, Japan 4 u9 b; E1 Z0 J, E: ?8 G  q
8Izumi Municipal Hospital, Osaka 594-0071, Japan
  K  {8 p) ~. W5 }* k6 T5 ]4 R9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
# q5 c& i+ O* [( Y& M$ MCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp   _$ Y9 l9 z1 d6 v
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. 9 U( ?4 [. t. O. K/ ?
) G! p/ p; b; \# F/ n" `1 G+ T
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
4 ]) w7 ?6 S) G+ R, a2 b( p/ @4 z7 Z$ z/ b( X% V8 F8 Y# E; Z. b
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato : a) a) W  V& A2 j& `' P; i6 B
6 k$ ~$ r( @- i
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
2 h+ y! y: X7 O* Z2 u6 S; g
# m0 n  Q/ A. {! J0 C: TPublished online on: Thursday, December 1, 2011
/ `! u3 D, K" B; _
9 X8 z( ?9 N& k. f- gDoi: 10.3892/ol.2011.507 : K2 w! {4 q) n7 S. r0 i
) V, U6 z" H. B
Pages: 405-410 7 C# S: T+ Z7 U/ G2 x% c  V1 M' l

6 `/ ]: O1 Z, u  O. O, kAbstract:
3 o7 \, p9 n# gS-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
( c2 @; Q1 x1 f' a2 t$ t( W% q+ G
$ w  C8 \/ {7 _3 `' z2 M
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population" p; J2 w" S$ s9 j- O4 p* f6 @
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
- a7 @2 |8 J: r, @& J' d# V$ c+ Author Affiliations
) ~7 I3 c% P$ x- G1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
+ z) W4 q# \. _, L- G6 x2Department of Thoracic Surgery, Kyoto University, Kyoto " B( K& e2 r. ?( g$ c3 t
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
) x. M" V/ W. a) C- u& V&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp ! U4 u6 f; v9 F: q; N0 n
Received September 3, 2010. - f/ ^) ^5 B9 f, d( R& S' c
Revision received November 11, 2010. 8 W9 ?3 f1 e) q
Accepted November 17, 2010. 0 {4 _  Y" s/ m( [" a1 n- L4 T
Abstract
6 s& M: C! V. c8 l& D1 [/ ZBackground: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed. ) t" {& q4 U. V) |. f& t) W
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. 6 A" c9 c! g- h5 n$ U5 Q& I
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
" s: X3 j7 x" r/ g4 `1 YConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. ) x- E0 H( p0 B; F% _% u7 i+ K  d
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
: C2 f( X2 Q, l: |今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?# J9 T2 a% \2 ^
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy8 }+ H' Z% n1 L3 y
http://clinicaltrials.gov/ct2/show/NCT015235871 E$ a, b8 M# [6 c

( q2 |: H, W( T: B- a$ LBIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC$ l9 [- c6 g% R% `/ W, W! I
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑
1 f- {, \( P9 g4 _# E; }" {+ l) ]/ z! U7 e0 A. j$ t
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
( H7 U: e0 w; s, [3 t至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53
" n1 _8 |4 J2 x! L$ j7 [9 r5 V从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。0 _6 p; q* x& A( {7 m
至今为止,未出 ...
( ]( l8 s& H. G5 x
没有副作用是第一追求,效果显著是第二追求。, Z6 D' k+ [# y) @8 \
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表